LIQUICHEK ANTI-SCL-70 CONTROL, POSITIVE, CATALOG #116

K024226 · Bio-Rad · LKJ · Jan 10, 2003 · Immunology

Device Facts

• Record ID: K024226
• Device Name: LIQUICHEK ANTI-SCL-70 CONTROL, POSITIVE, CATALOG #116
• Applicant: Bio-Rad
• Product Code: LKJ · Immunology
• Decision Date: Jan 10, 2003
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 866.5100
• Device Class: Class 2

Intended Use

The Liquichek™ Anti-Scl-70, Positive, is intended for use as an unassayed quality control to monitor indirect immunofluorescent testing for the detection of Scl-70 autoantibodies.

Device Story

Liquichek Anti-Scl-70 Control, Positive is a human serum-based, liquid, unassayed quality control material. It is used by laboratory personnel to monitor the performance of indirect immunofluorescent testing for Scl-70 autoantibodies. The control provides a known positive sample to verify assay accuracy and precision. It is stored at 2-8°C and remains stable for 60 days once opened. By providing a consistent reference, it helps ensure the reliability of clinical diagnostic results for autoimmune conditions.

Clinical Evidence

No clinical data. Stability studies were performed to validate shelf life (2 years at 2-8°C) and open-vial stability (60 days at 2-8°C).

Technological Characteristics

Human serum matrix with added preservatives. Liquid form. Unassayed. Storage at 2-8°C. No electronic or software components.

Indications for Use

Indicated for use as an unassayed quality control to monitor indirect immunofluorescent testing for the detection of Scl-70 autoantibodies in clinical laboratory settings.

Regulatory Classification

Identification

An antinuclear antibody immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the autoimmune antibodies in serum, other body fluids, and tissues that react with cellular nuclear constituents (molecules present in the nucleus of a cell, such as ribonucleic acid, deoxyribonucleic acid, or nuclear proteins). The measurements aid in the diagnosis of systemic lupus erythematosus (a multisystem autoimmune disease in which antibodies attack the victim's own tissues), hepatitis (a liver disease), rheumatoid arthritis, Sjögren's syndrome (arthritis with inflammation of the eye, eyelid, and salivary glands), and systemic sclerosis (chronic hardening and shrinking of many body tissues).

Predicate Devices

• Liquichek™ Anti-Scl-70 Control, EIA (K984475)

Submission Summary (Full Text)

{0}------------------------------------------------

## Summary of Safety and Effectiveness Liquichek™ Anti-Scl-70 Control, Positive

### 1.0 Submitter

Bio-Rad Laboratories 9500 Jeronimo Road. Irvine, California 92618-2017 Telephone: [phone] [phone] Fax:

## Contact Person

Yvette Lloyd Senior Requlatory Affairs Specialist Telephone: [phone]

## Date of Summary Preparation

December 20, 2002

### 2.0 Device Identification

| Product Trade Name: | Liquichek TM Anti-Scl-70 Control, Positive |
|---------------------|--------------------------------------------|
| Common Name: | Anti-Scl-70 Antibody, Antigen and Control |
| Classifications: | Class II |
| Product Code: | 82LKJ |
| Regulation Number: | 21 CFR 866.5100 |

#### 3.0 Device to Which Substantial Equivalence is Claimed

Liquichek™ Anti-Scl-70 Control, EIA Bio-Rad Laboratories

510 (k) Number: K984475

### 4.0 Description of Device

This product is prepared from human serum with added preservatives. The control is provided in liquid form for convenience.

# JAN 1 0 2003

Kory22le

{1}------------------------------------------------

### Statement of Intended Use 5.0

The Liquichek™ Anti-Scl-70, Positive, is intended for use as an unassayed quality control to monitor indirect immunofluorescent testing for the detection of Scl-70 autoantibodies.

### Comparison of the new device with the Predicate Device 6.0

This control is substantially equivalent to the following quality control material for autoimmune analysis that is currently in the market:

Liquichek™ Anti-Scl-70 Control, EIA Bio-Rad Laboratories

510 (k) Number: K984475

Table 1. Similarities and Differences between new and predicate device.

| Characteristics | Liquichek™ Anti-Scl-70 Control, Positive<br>(New Device) | Liquichek™ Anti-Scl-70 Control, EIA<br>(Predicate Device) |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Similarities | | |
| Matrix | Human Serum | Human Serum |
| Storage<br>(Unopened) | 2°C to 8°C<br>until expiration date | 2°C to 8°C<br>until expiration date |
| Form | Liquid | Liquid |
| Analyte | Anti-Scl-70 | Anti-Scl-70 |
| Value Assignment | Unassayed | Unassayed |
| Differences | | |
| Intended Use | The Liquichek™ Anti-Scl-70, Positive, is intended for use as an unassayed quality control to monitor indirect immunofluorescent testing for the detection of Scl-70 autoantibodies. | The Liquichek™ Anti-Scl-70 Control, EIA is intended for use as an unassayed quality control to monitor enzyme immunoassay procedures for the detection of scl-70 autoantibodies. |
| Stability<br>(Opened) | Once opened the analyte will be stable for 60 days. | Once opened the analyte will be stable for 30 days. |

{2}------------------------------------------------

### 7.0 Summary of Performance Data

Stability studies have been performed to determine the open vial stability and shelf life for the Liquichek™ Anti-Scl-70 Control, Positive. Product claims are as follows:

- Once the control is opened the analyte will be stable for 60 days when 7.1 stored tightly capped at 2 to 8°C.
- 7.2 The control is stable for 2 years when stored unopened at 2 8°C.

Real time studies will be ongoing to support the shelf life of this product.

All supporting data is retained on file at Bio-Rad Laboratories.

{3}------------------------------------------------

Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing right, with flowing lines representing hair or clothing.

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

## JAN 1 0 2003

Ms. Yvette Lloyd Senior Regulatory Affairs Specialist Bio-Rad Laboratories, QSD 9500 Jeronimo Road Irvine, CA 92618-2017

Re: k024226 Trade/Device Name: Liquichek" Anti-Scl-70 Control, Positive Regulation Number: 21 CFR 866.5100 Regulation Name: Antinuclear antibody immunological test system Regulatory Class: Class II Product Code: LKJ Dated: December 20, 2002 Received: December 23, 2002

Dear Ms. Lloyd

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

{4}------------------------------------------------

### Page 2 –

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Steven Sutman

Steven I. Gutman, M.D., M.B.A. Director Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

510 (k) Number (if known):____________________________________________________________________________________________________________________________________________________

Liquichek™ Anti-Scl-70 Control, Positive Device Name:

Indications for Use:

Liquichek Anti-Scl-70, Positive, is intended for use as an unassayed quality control to monitor indirect immunofluorescent testing for the detection of Scl-70 autoantibodies.

(PLEASE DO NOT WRITE BELOW THE LINE-CONINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription use

Over-the Counter use__________________________________________________________________________________________________________________________________________________________

A.P. Reeves for J. Bautista

or

(Division Sign-Off) (Division of Clinical Laboratory Devices on 4 1 2 2 h 510(k) Number ----------